Search Results - Stanislas Blein
- Showing 1 - 2 results of 2
-
1
Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity by Jeremy Loyau, Thierry Monney, Marco Montefiori, Fedir Bokhovchuk, Jeremy Streuli, Matthew Blackburn, Arnaud Goepfert, Lydia N. Caro, Samitabh Chakraborti, Stefania De Angelis, Camille Grandclément, Stanislas Blein, M. Lamine Mbow, Ankita Srivastava, Mario Perro, Stefano Sammicheli, Eugene A. Zhukovsky, Michael R. Dyson, Cyrille Dreyfus
Published in mAbs (2025-12-01)Get full text
Article -
2
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis by Barbara Rewerska, MD, Lawrence D. Sher, MD, Sady Alpizar, MD, Sylvia Pauser, MD, Grazyna Pulka, MD, Neelufar Mozaffarian, MD, PhD, Yacine Salhi, PhD, Camille Martinet, MS, Wafaa Jabert, MS, Girish Gudi, PhD, Vinu CA, MPharm, MSc, Sunitha GN, PhD, Julie Macoin, MSc, Victor Anstett, MS, Riccardo Turrini, PhD, Marie-Agnès Doucey, PhD, Stanislas Blein, PhD, Cyril Konto, MD, Martina Machkova, MD
Published in Journal of Allergy and Clinical Immunology: Global (2024-02-01)Get full text
Article